Highlights Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
436.27 ^USD	-2.35%		-0.56%	-3.77%

04-10	RBC Trims Price Target on Vertex Pharmaceuticals to $541 From $543, Keeps Outperform Rating	MT
04-09	Evercore ISI Adjusts Vertex Pharmaceuticals PT to $535 From $530, Maintains Outperform Rating	MT

Highlights

04-07	Halozyme Unit Enters License Deal With Vertex Pharmaceuticals for Hypercon Technology	MT
04-01	Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor)	CI
04-01	Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older	RE
03-31	Vertex Pharmaceuticals Incorporated Completes Submission of Biologics Licensing Application for Povetacicept to the U.S. Food and Drug Administration	CI
03-09	Vertex Pharmaceuticals Incorporated Announces Positive Interim Analysis Results for Povetacicept in Rainier Phase 3 Trial	CI
03-05	Vertex Pharmaceuticals Incorporated Presents New Data on JOURNAVX for Effective Pain Management Following Aesthetic and Reconstructive Procedures	CI
02-13	Tranche Update on Vertex Pharmaceuticals Incorporated's Equity Buyback Plan announced on May 19, 2025.	CI
02-12	Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand	DJ
02-12	Vertex Pharmaceuticals Q4 Non-GAAP Earnings, Revenue Rise	MT
02-12	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q4 Revenue $3.19B, vs. FactSet Est of $3.18B	MT
02-12	Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Adjusted EPS $5.03, vs. FactSet Est of $5.11	MT
02-12	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q4 Adjusted EPS $5.03 per Share, vs. FactSet Est of $5.11	MT
02-12	Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q4 Revenue $3.19B, vs. FactSet Est of $3.18B	MT
02-12	Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments	RE
02-12	Vertex Pharmaceuticals Incorporated Provides Earnings Guidance for the Full Year 2026	CI
02-12	Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-09	Zonebourse Corporate Earnings Calendar: Week of February 9 to 13, 2026
02-03	WuXi Biologics Inc. and Vertex Pharmaceuticals Incorporated Sign License and Research Service Agreement for T-Cell Engager	CI
01-29	Satellos Bioscience Inc. Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs	CI
12-06	Vertex Pharmaceuticals Incorporated Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions	CI
12-06	Vertex's gene therapy shows promise in younger children with blood disorders	RE
12-03	Wall Street's Dovish Delusion?
11-13	Worldwide Healthcare improves in first-half; sees lower final dividend	AN
11-08	Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week	CI
11-06	US FDA awards six more fast-track vouchers to speed drug reviews	RE